Ali, T., Roberts, D.N. and Tierney, W.M.(2009) Long-term safety concerns with proton pump inhibitors. Am J Med122: 896-903.
2.
Athmann, C., Zeng, N., Scott, D.R. and Sachs, G. ( 2000) Regulation of parietal cell calcium signaling in gastric glands. Am J Physiol Gastrointest Liver Physiol279: G1048-G1058.
3.
Bakke, I., Qvigstad, G., Brenna, E., Sandvik, A.K. and Waldum, H.L. ( 2000) Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: A study by elutriation centrifugation. Acta Physiol Scand169: 29-37.
4.
Bakke, I., Qvigstad, G., Sandvik, A.K. and Waldum, H.L. ( 2001) The cck-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol36: 1128-1133.
5.
Bernersen, B., Johnsen, R., Bostad, L., Straume, B., Sommer, A.I. and Burhol, P.G. ( 1992) Is Helicobacter pylori the cause of dyspepsia? BMJ304: 1276-1279.
6.
Bjornsson, E., Abrahamsson, H., Simren, M., Mattsson, N., Jensen, C., Agerforz, P. et al. (2006) Discontinuation of proton pump inhibitors in patients on long-term therapy: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther24: 945-954.
7.
Bolling-Sternevald, E., Lauritsen, K., Aalykke, C., Havelund, T., Knudsen, T., Unge, P. et al. (2002) Effect of profound acid suppression in functional dyspepsia: A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol37: 1395-1402.
8.
Carlsson, R., Dent, J., Bolling-Sternevald, E., Johnsson, F., Junghard, O., Lauritsen, K. et al. (1998) The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol33: 1023-1029.
9.
Crean, G.P., Marshall, M.W. and Rumsey, R.D. ( 1969) Parietal cell hyperplasia induced by the administration of pentagastrin (ICI 50,123) to rats. Gastroenterology57: 147-155.
10.
Drossman, D.A. ( 2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology130: 1377-1390.
11.
Farup, P.G., Hovde, O. and Breder, O. ( 1995) Are frequent short gastro-oesophageal reflux episodes the cause of symptoms in patients with non-ulcer dyspepsia responding to treatment with ranitidine? Scand J Gastroenterol30: 829-832.
12.
Ford, A.C., Moayyedi, P., Jarbol, D.E., Logan, R.F. and Delaney, B.C. ( 2008) Meta-analysis: Helicobacter pylori ‘test and treat’ compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther28: 534-544.
13.
Fossmark, R., Johnsen, G., Johanessen, E. and Waldum, H.L. ( 2005) Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther21: 149-154.
14.
Katelaris, P.H., Tippett, G.H., Norbu, P., Lowe, D.G., Brennan, R. and Farthing, M.J. ( 1992) Dyspepsia, Helicobacter pylori, and peptic ulcer in a randomly selected population in India. Gut33: 1462-1466.
15.
Kleveland, P.M., Waldum, H.L. and Larsson, H. ( 1987) Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol22: 705-713.
16.
Marshall, B.J. and Warren, J.R. ( 1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet1: 1311-1315.
17.
Martinsen, T.C., Bergh, K. and Waldum, H.L. ( 2005) Gastric juice: A barrier against infectious diseases. Basic Clin Pharmacol Toxicol96: 94-102.
18.
Miller, L.S., Vinayek, R., Frucht, H., Gardner, J.D., Jensen, R.T. and Maton, P.N. ( 1990) Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology98: 341-346.
19.
Moayyedi, P., Soo, S., Deeks, J., Delaney, B., Harris, A., Innes, M. et al. (2006) Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev: CD002096.
20.
Myren, J. ( 1983) The natural history of peptic ulcer- views in the 1980s . Scand J Gastroenterol18: 993-997.
21.
Nyren, O. ( 1991) Secretory abnormalities in functional dyspepsia. Scand J Gastroenterol182(Suppl): 25-28.
22.
Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelman, J.H., Orentreich, N. et al. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med325: 1127-1131.
23.
Qvigstad, G., Qvigstad, T., Westre, B., Sandvik, A.K., Brenna, E. and Waldum, H.L. ( 2002) Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS110: 132-139.
Reimer, C., Sondergaard, B., Hilsted, L. and Bytzer, P.(2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology137: 80-87.
Schindlbeck, N.E., Heinrich, C., Konig, A., Dendorfer, A., Pace, F. and Muller-Lissner, S.A. ( 1987) Optimal thresholds, sensitivity, and specificity of long-term Ph-metry for the detection of gastroesophageal reflux disease. Gastroenterology93: 85-90.
28.
Sharma, B.K., Walt, R.P., Pounder, R.E., Gomes, M.D., Wood, E.C. and Logan, L.H. ( 1984) Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut25: 957-964.
29.
Sjoblom, S.M., Sipponen, P., Miettinen, M., Karonen, S.L. and Jrvinen, H.J. ( 1988) Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy20: 52-56.
30.
Steen, J., Herning, M., Christiansen, P.M. and Rehfeld, J.F. ( 1980) Relationship between basal serum gastrin concentrations and gastric acid secretion in peptic ulcer disease. Scand J Gastroenterol15: 949-952.
31.
Talley, N.J., Locke, G.R., Lahr, B.D., Zinsmeister, A.R., Cohard-Radice, M., D’elia, T.V. et al. (2006) Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther23: 923-936.
32.
Talley, N.J., Meineche-Schmidt, V., Pare, P., Duckworth, M., Raisanen, P., Pap, A. et al. (1998) Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies) . Aliment Pharmacol Ther12: 1055-1065.
33.
Talley, N.J., Vakil, N., Ballard II, E.D. and Fennerty, M.B. ( 1999) Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med341: 1106-1111.
34.
Talley, N.J., Vakil, N., Lauritsen, K., Van Zanten, S.V., Flook, N., Bolling-Sternevald, E. et al. (2007) Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: Does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther26: 673-682.
35.
Van Marrewijk, C.J., Mujakovic, S., Fransen, G.A., Numans, M.E., De Wit, N.J., Muris, J.W. et al. (2009) Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (Diamond study): A primary-care-based randomised controlled trial. Lancet373: 215-225.
36.
Villako, K., Tamm, A., Savisaar, E. and Ruttas, M. ( 1976) Prevalence of antral and fundic gastritis in a randomly selected group of an Estonian rural population. Scand J Gastroenterol11: 817-822.
37.
Waldum, H.L., Arnestad, J.S., Brenna, E., Eide, I., Syversen, U. and Sandvik, A.K. ( 1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut39: 649-653.
38.
Waldum, H.L., Lehy, T., Brenna, E., Sandvik, A.K., Petersen, H., Sognen, B.S. et al. (1991a) Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol26: 23-35.
39.
Waldum, H.L., Sandvik, A.K., Brenna, E. and Petersen, H. ( 1991b) Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut32: 698-701.
40.
Wong, W.M., Wong, B.C., Hung, W.K., Yee, Y.K., Yip, A.W., Szeto, M.L. et al. (2002) Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut51: 502-506.
41.
Zamcheck, N., Grable, E., Ley, A. and Norman, L. ( 1955) Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med252: 1103-1110.
